KZIA Kazia Therapeutics Limited
Listings ·
Ordinary shares rose to 5,667,995,734 from 809,418,734 in six months. Nasdaq confirmed on 18 December 2025 that the company had regained compliance with Listing Rule 5550(b).
The deal has no common warrant coverage but includes prefunded warrants. Kazia expects net proceeds of approximately $46.5 million and says its cash runway would extend into the second half of 2028.
The company expects to file its annual report for the year ended June 30, 2025 no later than the fifteenth calendar day after the due date.
Kazia Therapeutics Limited is an emerging oncology-focused biotechnology company with a portfolio of development candidates across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications. Its lead program is paxalisib, formerly known as GDC-0084, an investigational brain-penetrant inhibitor of the PI3K, Akt and mTOR pathway that was designed to treat brain cancer. Genentech developed paxalisib, and Kazia entered a worldwide exclusive license for the asset in October 2016. The company says paxalisib is the only PI3K inhibitor in mainstream clinical development known to cross the blood-brain barrier. Its clinical strategy rests on three pillars: adult brain cancer, pediatric brain cancer and brain metastases. In the adult glioblastoma program, paxalisib was tested in GBM AGILE, a phase II/III adaptive platform study sponsored by the Global Coalition for Adaptive Research. The paxalisib arm did not graduate to the second stage, and approximately 150 patients were enrolled in the first stage. The filing says paxalisib has orphan drug designation for glioblastoma and glioma and Fast Track designation for glioblastoma.
| Product or program | What it is | Stage |
|---|---|---|
| Paxalisib (GDC-0084) | Brain-penetrant PI3K, Akt and mTOR pathway inhibitor designed to treat brain cancer | investigational |
| Line | FY ended Jun 30, 2025 | FY ended Jun 30, 2024 |
|---|---|---|
| Revenue | A$42,000 | A$2.3 million |
| Research and development | A$7.3 million | A$17.4 million |
| Net income (loss) | -A$20.7 million | -A$26.8 million |
| Cash from operations | -A$13.3 million | -A$9.6 million |
| Cash and equivalents | A$4.3 million | A$1.7 million |
Our latest story on this, dated Mar 30, 2026: "Kazia reports AUD 69.46 million cash after US$46.51 million PIPE in half-year report". The story links the filing or release it is based on. Read the story.
Kazia Therapeutics Limited trades under the ticker KZIA on NASDAQ.
Kazia Therapeutics Limited is listed on NASDAQ.
The SEC Central Index Key (CIK) for Kazia Therapeutics Limited is 1075880. Its filings are on SEC EDGAR.
809,418,734 shares as of 2025-06-30, per the cover page of its 20-F filed 2025-11-07.
Our directory records Kazia Therapeutics Limited under Australia.
Our directory classifies Kazia Therapeutics Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Kazia Therapeutics Limited is US48669G3039.
aibio.space lists Kazia Therapeutics Limited among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as C3.
Kazia Therapeutics Limited is an emerging oncology-focused biotechnology company with a portfolio of development candidates across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications. Its lead program is paxalisib, formerly known as GDC-0084, an investigational brain-penetrant inhibitor of the PI3K, Akt and mTOR pathway that was designed to treat brain cancer.
Paxalisib (GDC-0084): Brain-penetrant PI3K, Akt and mTOR pathway inhibitor designed to treat brain cancer Stage: investigational.
Our latest story on Kazia Therapeutics, dated Mar 30, 2026: "Kazia reports AUD 69.46 million cash after US$46.51 million PIPE in half-year report". Ordinary shares rose to 5,667,995,734 from 809,418,734 in six months. Nasdaq confirmed on 18 December 2025 that the company had regained compliance with Listing Rule 5550(b). Source.
From our story of Mar 30, 2026: The report's dollar figures are Australian dollars: the going concern note gives the cash balance of $69,459,980 at 31 December 2025 as AUD 69.46 million. Source.
Our latest distress story, dated Oct 31, 2025: "Kazia Therapeutics says 20-F is late as audit procedures are not complete". The company expects to file its annual report for the year ended June 30, 2025 no later than the fifteenth calendar day after the due date. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio